{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T11:52:47Z","timestamp":1789645967447,"version":"4.0.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1097\/01.bor.0000434673.85515.89","type":"journal-article","created":{"date-parts":[[2013,9,21]],"date-time":"2013-09-21T13:50:05Z","timestamp":1379771405000},"page":"747-752","source":"Crossref","is-referenced-by-count":57,"title":["The spectrum of statin myopathy"],"prefix":"10.1097","volume":"25","author":[{"given":"Payam","family":"Mohassel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew L.","family":"Mammen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-13-20210128","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170000 participants in 26 randomised trials.","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"R2-13-20210128","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1007\/s10557-005-5686-z","article-title":"Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients - the PRIMO study.","volume":"19","author":"Bruckert","year":"2005","journal-title":"Cardiovasc Drugs Ther"},{"key":"R3-13-20210128","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/mus.21486","article-title":"Immune-mediated necrotizing myopathy associated with statins.","volume":"41","author":"Grable-Esposito","year":"2010","journal-title":"Muscle Nerve"},{"key":"R4-13-20210128","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.nmd.2006.10.007","article-title":"Progressive myopathy with up-regulation of MHC-I associated with statin therapy.","volume":"17","author":"Needham","year":"2007","journal-title":"Neuromuscul Disord"},{"key":"R5-13-20210128","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy.","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"key":"R6-13-20210128","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme a reductase (HMGCR) in patients with statin-associated autoimmune myopathy.","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"key":"R7-13-20210128","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1002\/acr.20662","article-title":"Rarity of anti3-hydroxy-3-methylglutaryl-coenzyme A reductase antibodies in statin users, including those with self-limited musculoskeletal side effects.","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"},{"key":"R8-13-20210128","doi-asserted-by":"crossref","first-page":"e002040","DOI":"10.1136\/bmjopen-2012-002040","article-title":"Assessment of statin-associated muscle toxicity in Japan: a cohort study conducted using claims database and laboratory information.","volume":"3:pii","author":"Chang","year":"2013","journal-title":"BMJ Open"},{"key":"R9-13-20210128","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1002\/pds.1603","article-title":"The safety of rosuvastatin in comparison with other statins in over 100000 statin users in UK primary care.","volume":"17","author":"Garcia-Rodriguez","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"R10-13-20210128","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.clinthera.2007.02.008","article-title":"Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy.","volume":"29","author":"Silva","year":"2007","journal-title":"Clin Ther"},{"key":"R11-13-20210128","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1016\/j.amjmed.2006.02.007","article-title":"Clinical perspectives of statin-induced rhabdomyolysis.","volume":"119","author":"Antons","year":"2006","journal-title":"Am J Med"},{"key":"R12-13-20210128","doi-asserted-by":"crossref","first-page":"52C","DOI":"10.1016\/j.amjcard.2005.12.010","article-title":"Statin safety: a systematic review.","volume":"97","author":"Law","year":"2006","journal-title":"Am J Cardiol"},{"key":"R13-13-20210128","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ejim.2012.01.004","article-title":"Statin induced myotoxicity.","volume":"23","author":"Sathasivam","year":"2012","journal-title":"Eur J Intern Med"},{"key":"R14-13-20210128","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1056\/NEJMoa0801936","article-title":"SLCO1B1 variants and statin-induced myopathy: a genomewide study.","volume":"359","author":"Link","year":"2008","journal-title":"N Engl J Med"},{"key":"R15-13-20210128","doi-asserted-by":"crossref","first-page":"E11","DOI":"10.1503\/cmaj.081785","article-title":"Association between statin-associated myopathy and skeletal muscle damage.","volume":"181","author":"Mohaupt","year":"2009","journal-title":"CMAJ"},{"key":"R16-13-20210128","doi-asserted-by":"crossref","first-page":"581","DOI":"10.7326\/0003-4819-137-7-200210010-00009","article-title":"Statin-associated myopathy with normal creatine kinase levels.","volume":"137","author":"Phillips","year":"2002","journal-title":"Ann Intern Med"},{"key":"R17-13-20210128","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1097\/CND.0b013e3182852558","article-title":"Outcomes of statin myopathy after statin withdrawal.","volume":"14","author":"Armour","year":"2013","journal-title":"J Clin Neuromusc Dis"},{"key":"R18-13-20210128","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.amjcard.2007.06.030","article-title":"Effect of coenzyme Q(10) supplementation on simvastatin-induced myalgia.","volume":"100","author":"Young","year":"2007","journal-title":"Am J Cardiol"},{"key":"R19-13-20210128","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1016\/j.amjcard.2006.12.063","article-title":"Effect of coenzyme q10 on myopathic symptoms in patients treated with statins.","volume":"99","author":"Caso","year":"2007","journal-title":"Am J Cardiol"},{"key":"R20-13-20210128","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.amjcard.2012.04.026","article-title":"Effect of coenzyme Q10 supplementation on statin-induced myalgias.","volume":"110","author":"Bookstaver","year":"2012","journal-title":"Am J Cardiol"},{"key":"R21-13-20210128","doi-asserted-by":"crossref","first-page":"80","DOI":"10.3109\/14017431.2012.756119","article-title":"No effect of combined coenzyme Q10 and selenium supplementation on atorvastatin-induced myopathy.","volume":"47","author":"Bogsrud","year":"2013","journal-title":"Scand Cardiovasc J"},{"key":"R22-13-20210128","doi-asserted-by":"crossref","first-page":"291","DOI":"10.2353\/ajpath.2010.091140","article-title":"Statin therapy and the expression of genes that regulate calcium homeostasis and membrane repair in skeletal muscle.","volume":"177","author":"Draeger","year":"2010","journal-title":"Am J Pathol"},{"key":"R23-13-20210128","first-page":"2012","article-title":"Does simvastatin cause more myotoxicity compared with other statins Ann P","volume":"43","author":"Backes","year":"2009","journal-title":"harmacother"},{"key":"R24-13-20210128","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1592\/phco.30.6.541","article-title":"Statin-associated muscle-related adverse effects: a case series of 354 patients.","volume":"30","author":"Cham","year":"2010","journal-title":"Pharmacotherapy"},{"key":"R25-13-20210128","doi-asserted-by":"crossref","first-page":"4087","DOI":"10.1002\/art.34673","article-title":"Antibody levels correlate with creatine kinase levels and strength in anti-HMG-CoA reductase-associated autoimmune myopathy.","volume":"64","author":"Werner","year":"2012","journal-title":"Arthritis Rheum"},{"key":"R26-13-20210128","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1002\/acr.21671","article-title":"Increased frequency of DRB111:01 in anti-HMG-CoA reductase-associated autoimmune myopathy.","volume":"64","author":"Mammen","year":"2012","journal-title":"Arthritis Care Res"}],"container-title":["Current Opinion in Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/01.bor.0000434673.85515.89","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,5,18]],"date-time":"2024-05-18T01:23:35Z","timestamp":1715995415000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00002281-201311000-00013"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":26,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013]]}},"URL":"https:\/\/doi.org\/10.1097\/01.bor.0000434673.85515.89","relation":{},"ISSN":["1040-8711"],"issn-type":[{"value":"1040-8711","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]}}}